Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Modus's Intended IPO to Spur Sickle Cell Drug R&D

Executive Summary

The first IPO for a pharmaceutical company nurtured by Karolinska Development is expected to involve Modus Therapeutics, which has changed its name from Dilaforette and is pursuing the development of a Phase II potential sickle cell therapy.

Advertisement

Related Content

Novartis Buys Selexys As Competitors Stumble In Sickle Cell
EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall
Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness
Innovative Bahraini Deal Inked For Sickle Cell Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel